Velmanase Alfa (Lamzede)

Velmanase alfa is an enzyme-replacement therapy for alpha-mannosidosis, an ultra-rare inherited disease in which a missing enzyme leaves mannose-rich sugar chains piling up inside cells instead of being broken down — driving recurrent infections, skeletal problems, hearing loss and progressive disability over a patient's lifetime. It's the first and, as of this review, only approved treatment for the disease anywhere, developed by the small Danish biotech Zymenex before Chiesi acquired the company in 2013 and carried it to market. The Phase 3 trial behind it is a genuinely mixed result worth stating plainly: it hit its biomarker endpoint cleanly, cutting a disease-driving blood marker by more than three-quarters, but its motor-function endpoint only trended toward improvement without reaching statistical significance — and the EU approved it in 2018 on that evidence nearly five years before the FDA did the same.

A missing enzyme, and oligosaccharides with nowhere to go

Alpha-mannosidosis is a rare, autosomal recessive lysosomal storage disease caused by mutations in the MAN2B1 gene, which normally codes for lysosomal alpha-mannosidase — an enzyme that breaks down mannose-containing oligosaccharides, byproducts of ordinary glycoprotein turnover inside every cell. Without enough working enzyme, those oligosaccharides accumulate inside lysosomes throughout the body instead of being cleared, producing a disease that typically presents with recurrent bacterial infections and hearing loss in early childhood, followed over years by skeletal abnormalities, muscle weakness, and in many patients progressive intellectual disability and ataxia. Zymenex A/S, a small Danish biotech, developed velmanase alfa — a recombinant form of the missing human enzyme, produced in Chinese hamster ovary cells — as a weekly intravenous enzyme-replacement therapy, receiving EU orphan drug designation for it in January 2005. Chiesi acquired Zymenex in 2013 and carried the drug the rest of the way through development. Because the recombinant enzyme is too large to cross the blood-brain barrier, it replaces alpha-mannosidase activity in the body generally but not in the central nervous system — which is why both the EU and US approvals are specifically for the disease's non-CNS manifestations, not the neurological ones.

The pivotal trial: a clean biomarker win, a motor-function endpoint that fell short

Velmanase alfa's pivotal evidence came from rhLAMAN-05 (NCT01681953), a 52-week, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial in 25 patients with alpha-mannosidosis, ages 6 to 35, that set two co-primary endpoints: change in serum oligosaccharide (a direct biochemical marker of the disease's core defect) and change in the 3-minute stair-climb test (3MSCT, a functional measure of muscle endurance). The trial hit its biomarker endpoint cleanly: mean serum oligosaccharide fell 77.6% in the velmanase alfa group versus 24.1% in the placebo group by week 52 (P<0.001). The functional endpoint told a genuinely different story — motor and pulmonary function measures, including the 3MSCT, showed only a trend toward improvement with treatment, most visible in the pediatric patients, without reaching statistical significance in the trial as designed (Borgwardt L, Guffon N, Amraoui Y, et al., "Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial," J Inherit Metab Dis 2018;41(6):1215-1223, PMID 29846843, DOI: 10.1007/s10545-018-0185-0).¹ That gap between a clear biomarker result and an inconclusive functional one is a real, disclosed limitation of the evidence base, not a detail either regulator glossed over — both approvals rest explicitly on the biomarker reduction as a reasonably likely predictor of clinical benefit in a disease this rare, the same kind of surrogate-endpoint reasoning this site's other ultra-rare-disease enzyme-replacement pages describe.

Twelve years of extension data, and a boxed warning for anaphylaxis

Because the pivotal trial's 25-patient cohort was so small, much of what's known about velmanase alfa's longer-term effect comes from two open-label extension studies, rhLAMAN-07 and rhLAMAN-09, which followed patients who'd completed earlier trials plus a handful of enzyme-replacement-naive patients (Lund AM, Pantel J, Borgwardt L, et al., "Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis," J Inherit Metab Dis 2018;41(6):1225-1233, PMID 29725868, DOI: 10.1007/s10545-018-0175-2)². A later follow-up analysis extends that safety and efficacy picture out to 12 years of continuous treatment in the longest-treated patients (Guffon N, Borgwardt L, Amraoui Y, et al., "Extended long-term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha-mannosidosis," J Inherit Metab Dis 2025;48(1):e12799, PMID 39381850, DOI: 10.1002/jimd.12799)³ — real, if necessarily uncontrolled, long-term evidence for a disease with no other approved treatment to compare against. Velmanase alfa's FDA label carries a boxed warning for severe hypersensitivity reactions, including anaphylaxis, that have occurred during and after infusion; the label reports these reactions occurred more often in patients who developed anti-drug antibodies (80%) than in those who didn't (20%), recommends considering premedication with antihistamines, antipyretics or corticosteroids, and requires cardiopulmonary resuscitation equipment be on hand during each infusion.

A five-year gap between EU and US approval

The European Commission approved velmanase alfa (as Lamzede) on 4 April 2018, under the EU's "exceptional circumstances" marketing-authorization pathway — a mechanism built specifically for diseases rare enough that a conventional, fully powered trial program isn't realistically achievable, requiring the manufacturer to continue submitting safety and efficacy data on an ongoing basis after approval rather than closing the file at launch. The FDA did not approve the same drug, on largely the same core evidence package, until 16 February 2023 (BLA 761278) — a gap of nearly five years, during which US patients with alpha-mannosidosis had no approved treatment option at all while European patients did. The FDA approval came with Fast Track, Orphan Drug and Rare Pediatric Disease designations attached, and covers the same non-CNS-manifestations population as the EU label; the agency's own review documents cite the same rhLAMAN-05 biomarker result as the central efficacy evidence. Neither regulator's public documentation attributes the gap to a specific disagreement over the data — Chiesi's FDA submission simply came later than its EU one — but the practical result was a real, multi-year transatlantic access gap for a small population of patients with an already severe, progressive disease.

Current status

Lamzede remains approved and actively marketed by Chiesi Global Rare Diseases in both the EU and the US, and remains the only approved treatment for alpha-mannosidosis anywhere — no competing enzyme-replacement therapy or alternative treatment has reached the market as of this review. Patients and families weighing it do so against a disease with a real, progressive natural history and a treatment with a genuinely mixed trial record: strong biochemical evidence that it does what it's designed to do, longer-term extension data that's encouraging but uncontrolled, and a functional-outcome question the original pivotal trial was simply too small to answer definitively.